The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

StocksUpdated•Originally published 8 May 2026•Updated 10 May 2026•

1 min read

Cytokinetics Closes $805 Million Public Offering of Common Stock

Key Facts

1Cytokinetics announced the closing of a public offering of 11,338,028 shares of common stock at a price of $71.00 per share.

2Gross proceeds from the offering reached approximately $805 million following the full exercise of the underwriters' option.

Cytokinetics has finalized its $805 million public offering, strengthening its balance sheet to fund strategic operational milestones. The capital raise coincides with the US launch of Myqorzo, which is already seeing promising early prescribing demand. Additionally, the company reported positive Phase 3 trial results for aficamten in treating non-obstructive hypertrophic cardiomyopathy (HCM). Despite this operational momentum, some analyst assessments suggest that CYTK stock may currently be overvalued. The proceeds are expected to accelerate research and development activities for the firm's cardiovascular pipeline. While investor demand remains robust as evidenced by the full exercise of the over-allotment option, the market is balancing clinical success against valuation concerns.

25 days ago

Version History

Version 125 days ago

What changed: Updated the story to include the Myqorzo launch, positive Phase 3 data for aficamten, and new analyst perspectives regarding stock valuation.